Recent Reflections on Immuno-Oncology - prIME Oncology

Recent Reflections on Immuno-Oncology

Advances in NSCLC, Melanoma, and Bladder Cancer

Not a member of My prIME? Join now for instant access.

Stay informed on key data in immune-oncology for non-small cell lung cancer, melanoma, and bladder cancer reported data. Don’t miss out!





1.75 AMA PRA Category 1 Credit

Release Date

Release Date

Apr 18, 2019

Expiration Date

Apr 18, 2020

Recent Reflections on Immuno-Oncology: Non-Small Cell Lung Cancer

Recent Reflections on Immuno-Oncology: Melanoma

Recent Reflections on Immuno-Oncology: Bladder Cancer

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with lung cancer, bladder cancer, and melanoma.

After successful completion of this educational activity, participants should be able to:

  • Evaluate clinical trial data assessing the efficacy and safety of immune checkpoint inhibitors for the management of patients with solid tumors
  • Develop optimal treatment plans utilizing immune checkpoint inhibitors for the treatment of solid tumors
  • Assess the rationale for using immune checkpoint inhibitors, alone, and in combination with chemotherapy or other novel agents, for the treatment of solid tumors
  • Formulate treatment plans to manage immune-related adverse events associated with the treatment with immune checkpoint inhibitors

This educational activity is supported by a grant from Merck Sharp and Dohme Corp.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Lung newsletter: 0.5
Bladder newsletter: 0.75
Melanoma newsletter: 0.5


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.75 hours

To contact Postgraduate Institute for Medicine please visit

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) –(scientific content reviewer/planner) – worked on non–CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
  • Zach Hartman, PhD (author) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Clovis Oncology; F. Hoffmann-La Roche Ltd; ImmunoGen; Merck KGaA, Darmstadt, Germany; Pfizer; Novartis Oncology; Puma Biotechnology; and Tesaro

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.